Navigation Links
SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations
Date:11/6/2009

The Recent NTSB Mandatory Sleep Apnea Testing Recommendations Are Expected To Become A Law Very Soon For Commercial Pilots And Drivers. It's Reported That In Current Tracking Industry, A Sleep Apnea Lab Testing Could Cost About $2,000 With A Waiting Period Of Up To Six Months. More Than 60% Of Diagnosed Apnea Patients Can Not Tolerate Standard CPAP Treatment. Dr. Jin Zhou Of SleepApneaUSA.net Proposed An Immediate Alternative Solution In Hope To Save Thousands Of Lives.

Hanover Park, IL (PRWEB) November 6, 2009 -- The recent NTSB mandatory recommendations for sleep apnea testing and treatment are expected to become a law very soon for commercial pilots and drivers due to the eminent public safety and tort liability litigation concerns. It's reported that in the current tracking industry, a sleep apnea lab testing could cost about $2,000 with a waiting period of up to six months. More than 60% of diagnosed apnea patients can not tolerate standard CPAP Treatment. Dr. Jin Zhou of SleepApneaUSA.net proposed an immediate alternative solution in hope to save thousands of lives, before the next pilot and driver can be tested in a standard lab, because it is well known that a driver with sleep apnea is much more dangerous than a drunk driver with DUI risk factors. Dr. Zhou proposed, to the government and the public, that all commercial pilots and drivers to be immediately tested for sleep apnea screening with a portable home sleep apnea test device, costing only about $500, that is FDA cleared, Medicare and FMCSA accepted, and that those with positive apnea results should be re-tested in a standard sleep lab and be treated immediately under standard medical programs with CPAP or surgery if indicated. In addition, Dr. Zhou offered an immediate alternative sleep apnea solution, ZHT (Zhou's Hypoxicology Therapy) for more than 60% of sleep apnea positive pilots and drivers who cannot tolerate CPAP and not indicat
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. SleepApneaUSA.net Announced An Alternative Sleep Apnea Solution For Commercial Pilots After NTSB Recommended Mandatory Sleep Apnea Certification For Testing And 'Successful Treatment'
2. SleepApneaUSA.net Announced New 2010 ZHT (Zhou's Hypoxicology Therapy) Certification Class For Sleep Apnea As A No-Surgery And No-Device Alternative
3. Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced
4. Metropolitan Chicago Breast Cancer Task Force Announced Members of Chicago Breast Cancer Quality Consortium
5. ERISAclaim.com Announced Free ERISA Webinar for Healthcare Overpayment Dispute and Claim Denials in Response to Increasing High Demand from the $6 Trillion Healthcare Denial Management Market
6. ERISAclaim.com Announced the Expansion of its ERISA Litigation Support for the Healthcare Claims in Response to Increasing High Demand from the $6 Trillion Healthcare Denial Management Market
7. First Annual Conference of National Association of Healthcare Advocacy Consultants (NAHAC) to Be Held Nov. 14-15; Board of Directors Announced
8. ERISAclaim.com Announced the Nation's First Certification Program for the ERISA Claim Appeal Specialist for Healthcare Providers and Managed-Care Payers
9. Launch of First Year-Round Annual Scientific Medical Meeting Announced at Health 2.0
10. Agenda Announced for Ionic Liquids 2009
11. National Greatness Contest Winners Announced

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wswire/-SentinelleMedicalInc.,aleadingmanufacturer...CalgaryScientificInc.,aleadingproviderofsoftwareen...s(TM)Breast4DAdvancedVisualizationsoftware. ,, ...ntWebclientbasedmedicalimagingofferinginthemarket....o-footprintaccess-requiringnosoftwaredownload,andr...
(Date:11/25/2009)...swire-USNewswire/--AnarticlebyJanetWoodcock,M.D.,d...h,titled"ADifficultBalance-PainManagement,DrugSafe...EnglandJournalofMedicine. ,, (Logo: http://www....Inthearticle,WoodcockdiscussesFDAeffortstostrikeab...itandmanagingtherisksposedbyvariousanalgesics.Asex...
(Date:11/25/2009)...usiness,andPressJoinEfforttoEducate ,, MEMPHIS...eNationalBipolarFoundationandtheMedicAlertFoundati...e"program,whichisnowbeingwidelyacceptedasapreventi...ionalBipolarFoundationreceivedaproclamationofendor...norofLouisianaMitchLandrieu.TheNationalBipolarFoun...
(Date:11/25/2009)...out of a collaboration between UCLA engineers and ...rly 10 million Americans who suffer from periphera...g of the arteries, peripheral arterial disease, or...rowed arteries reduce blood flow to the limbs. The...isease, heart attack and stroke, and its progressi...
(Date:11/25/2009)...matoid arthritis, could help newly diagnosed diabe... (HealthDay News) -- A drug commonly used to treat...ow also shows some promise in helping patients new...rituximab (Rituxan), helped patients keep producin...se had destroyed some of their pancreatic beta cel...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...ormation is Meaningful,and in Appropriate Context,...logy Association (AdvaMed) today expressed support...ionships with physicians by,putting forth key chan...ed innovation in medical technology relies on dire...
...inating against a variety of infectious diseases ...ther than needles has proved able to produce a st...wo new studies. , The results build on previous s...ines developed at the Michigan Nanotechnology Inst...
...in Florida and Texas, JACKSONVILLE, Fla. and BETH...TM) today announced an agreement to equip physicia...ing service under,Availity,s private label, CarePr...g of Blue Cross and Blue Shield of,Florida, Humana...
...6-month study , , TUESDAY, Feb. 26 (Healt...ins the antiretroviral drug tenofovir is safe for ...a six-month study of 200 women in India and the Un...le to adhere to a regimen of either daily or sex-d...
...nd Fund Health Needs, WASHINGTON, Feb. 26 A coal...a newspaper and radio advertising,campaign in supp...ky,s,cigarette tax by 70 cents per pack, reduce sm... Kentucky lawmakers to support House Bill,443, spo...
...s, Inc. (Nasdaq: ADLS ), a biopharmaceutical comp...ercialization of novel drugs in the,therapeutic ar... today,announced that it will present at Susquehan...cgi-bin/prnh/20080218/ALSLOGO ), Advanced Life Sc...
Other Medicine News:Health News:AdvaMed Supports Key Changes to Disclosure Legislation 2Health News:AdvaMed Supports Key Changes to Disclosure Legislation 3Health News:Nanoemulsion vaccines show increasing promise 2Health News:Nanoemulsion vaccines show increasing promise 3Health News:Nanoemulsion vaccines show increasing promise 4Health News:Availity Engages Prematics to Deploy Electronic Prescribing 2Health News:Availity Engages Prematics to Deploy Electronic Prescribing 3Health News:HIV Drug in Microbicide Gel Safe for Daily Use 2Health News:Health Groups Launch Ad Campaign Supporting 70-Cent Increase in Kentucky Cigarette Tax 2Health News:Advanced Life Sciences to Present at Susquehanna's Second Annual SIGnificant Investment Options in Healthcare Conference 2
(Date:11/25/2009)...-NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevicecompan...surgicaltreatmentsforthespine,announcedtodaythatit...5:30p.m.ET/2:30p.m.PT.Theconferencecallwillfocuson...sproductsandwillincludecommentsfrommanagementfollo...ersare1-877-407-4018fordomesticcallersand1-201-689...
(Date:11/25/2009)...er.comannouncesthatanewmarketresearchreportisavail...USMarketTrends&Analysis http://www.reportlink...et-Trends--Analysis.html ,, TheUSintranasaldru...capplicationsfromthedeliveryofconventionallocalthe...gs.Thefutureofthetechnologyhingesontotheeffectivee...
(Date:11/25/2009)...-- ChemoCentryx,Inc.,announcedtodaythatPhaseII/II...iveRandomizedOralTherapyEvaluationinCrohn,sdisease...erate-to-severeCrohn,sdiseasedemonstratedclinicale...Thestudydemonstratedevidenceofclinicalefficacyinth...reaseintheCrohn,sDiseaseActivityIndex(CDAI)inpatie...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Access Pharmaceuticals Provides Update on ProLindac 28TM 29 Phase 2 Ovarian Cancer Trial and Clinical Development Plan 47461 1Access Pharmaceuticals Provides Update on ProLindac 28TM 29 Phase 2 Ovarian Cancer Trial and Clinical Development Plan 47461 2Access Pharmaceuticals Provides Update on ProLindac 28TM 29 Phase 2 Ovarian Cancer Trial and Clinical Development Plan 47461 3Access Pharmaceuticals Provides Update on ProLindac 28TM 29 Phase 2 Ovarian Cancer Trial and Clinical Development Plan 47461 4BayCare Named CIO 100 Award Winner by CIO Magazine 47458 1BayCare Named CIO 100 Award Winner by CIO Magazine 47458 2BayCare Named CIO 100 Award Winner by CIO Magazine 47458 3National Museum of Dentistry Opens New Smile Experience Exhibition Recognizes Dr Irwin Smigel as Father of Aesthetic Dentistry 47455 1National Museum of Dentistry Opens New Smile Experience Exhibition Recognizes Dr Irwin Smigel as Father of Aesthetic Dentistry 47455 2National Museum of Dentistry Opens New Smile Experience Exhibition Recognizes Dr Irwin Smigel as Father of Aesthetic Dentistry 47455 3
...7 Trius Therapeutics, Inc. announced,today that i...-701, an,antibacterial drug candidate intended for...bacterial infections, including those caused by MR...ght subject single and,multiple ascending dose tri...tics of the oral dosage form of the drug and will ...
...uided Nanoparticles May Deliver Treatments to Huma... used,magnetic fields and tiny iron-bearing partic...ood vessels. The research, done in animals, may le...o repair injured or diseased,organs in people., (...07/DC10966 ), The study team, led by Robert J. L...
Other Medicine Technology:Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701 2Researchers Use Magnetism to Target Cells to Animal Arteries 2Researchers Use Magnetism to Target Cells to Animal Arteries 3Researchers Use Magnetism to Target Cells to Animal Arteries 4
...y that a second mirror adds, then you may want to ...same 1.5x magnification as the G-1 but offers two ... Available in standard (flange) or new glass NF (n...anged" model for laser use. Provides broader vie...
Direct Image AFX SSV®
Direct Image High-Mag SSV®
Direct Image Mid Field
Medicine Products: